Biocon Group's Q3FY26 revenue grew 9% YoY to ₹ 4,173 Cr, with net profit surging 475% YoY to ₹ 144 Cr.

Generics revenue jumped 24% (₹ 851 Cr) from new GLP-1 launches.

Biosimilars rose 9% (₹ 2,497 Cr), boosting segment EBITDA by 44% with strong North America traction.

CRDMO dipped 3% (₹ 917 Cr) due to a temporary client issue.

A key strategic move is integrating Biocon and Biocon Biologics to simplify structure, enhance financials, and leverage synergies across their diverse portfolio (biosimilars, insulins, GLPs) in high-need areas.

Syngene (CRDMO) aims to capitalize on global outsourcing trends by expanding client relationships and capacity.

Biocon strengthened its balance sheet with a ₹ 4,500 Cr QIP, saving ~₹ 300 Cr annually in interest.

Product launches are accelerating, including the first interchangeable biosimilar Aspart in the US, plus new GLP-1s, oncology, and immunology biosimilars.

Major capex is largely complete; Generics received positive US FDA EIRs.

Syngene extended its BMS partnership to 2035. Net Debt/EBITDA improved to 2.8x (proforma 9M FY26) from 4.3x in FY23. Management expects sustainable growth from integration and a robust product pipeline targeting affordable global access.

Major capex is finalized, positioning Biocon for demand for 5+ years.

CRDMO anticipates improved capacity utilization.